



D | Pharmacology,
P | Pharmacotherapy
P | and Pharmaceutical Care

UNIVERSITÉ LIBRE DE BRUXELLES



Extraction, Qualification, and Structuring of Herb-Drug Interaction Relations: Artificial Intelligence Serving Pharmaco- and Phyto-Vigilance



CNUUDE Anthony
Co-promoters :
SOUARD Florence
LENAERTS Tom



About me

- **Studies**

- Master in Pharmaceutical Sciences – ULB
- Master in Bioinformatics and Modelling – ULB



About me

- **Studies**



- Master in Pharmaceutical Sciences – ULB
- Master in Bioinformatics and Modelling – ULB

- **Position**

- Teaching Assistant – Department of Informatics
- Pharmacology, Pharmacotherapy and Pharmaceutical care - ULB
- Machine Learning Group - ULB
- CENTAL – UCLouvain



Bioinformatics




(c)




Herb-Drug Interactions




Herb-Drug Interactions




Herb-Drug Interactions




A case of interaction



A case of interaction



A case of interaction




Case Reports > [Ann Pharmacother.](#) 2000 Sep;34(9):1013-6. doi: 10.1345/aph.10088.

Drug interaction between St. John's wort and cyclosporine

G W Barone¹, B J Gurley, B L Ketel, [M L Lightfoot](#), S R Abul-Ezz

A 29-year-old white woman who received a cadaveric kidney and pancreas transplant, with stable organ function and stable cyclosporine concentrations began self-medicating with St. John's wort. After taking St. John's wort supplements for four to eight weeks, her cyclosporine concentrations became subtherapeutic; this was associated with organ rejection. Four weeks after stopping St. John's wort, her cyclosporine concentrations again became therapeutic. Subsequent to this rejection episode, she has developed chronic rejection and now has returned to dialysis.

A case of interaction



A 29-year-old white woman who received a cadaveric kidney and pancreas transplant, with stable organ function and stable cyclosporine concentrations began self-medicating with St. John's wort. After taking St. John's wort supplements for four to eight weeks, her cyclosporine concentrations became subtherapeutic; this was associated with organ rejection. Four weeks after stopping St. John's wort, her cyclosporine concentrations again became therapeutic. Subsequent to this rejection episode, she has developed chronic rejection and now has returned to dialysis.

Herbal product consumption

Consumption of herbal products

- 2012: 18% of U.S. adults
- 2017: 25% of U.S. adults
 - Food? Spices? Drink?
 - Do they report? Do they know?

Herbal product consumption

Consumption of herbal products

- 2012: 18% of U.S. adults
- 2017: 25% of U.S. adults

→ Food? Spices? Drink?

→ Do they report? Do they know?

Case Reports > [Ann Pharmacother.](#) 2000 Sep;34(9):1013-6. doi: 10.1345/aph.10088.

Drug interaction between St. John's wort and cyclosporine

[G W Barone](#) ¹, [B J Gurley](#), [B L Ketel](#), [M L Lightfoot](#), [S R Abul-Ezz](#)




A 29-year-old white woman who received a cadaveric kidney and pancreas transplant, with stable organ function and stable cyclosporine concentrations began self-medicating with St. John's wort. After taking St. John's wort supplements for four to eight weeks, her cyclosporine concentrations became subtherapeutic; this was associated with organ rejection. Four weeks after stopping St. John's wort, her cyclosporine concentrations again became therapeutic. Subsequent to this rejection episode, she has developed chronic rejection and now has returned to dialysis.

The problem



Number of articles in PubMed by year
using search query (herb-drug or supplement*) AND interact*




- The quantity of information is growing exponentially
- Clinicians **lack time** to consult literature
- A solution: **databases**

The problem



Number of articles in PubMed by year
using search query (herb-drug or supplement*) AND interact*



- The quantity of information is growing exponentially
- Clinicians **lack time** to consult literature
- A solution: **databases**



**Herb Drug Interaction
Database**

<https://hedrine.ulb.be>

Hedrine



Interactions entre Ail et warfarine

Etudes et cas cliniques

Mécanisme : Case report (Ail + warfarine) ●

Force Forte

Effets: avéré

Case report : hématome épidual spontané sous 2g/jour d'ail pendant une période indéterminée D'autres épisodes de saignements liés à la consommation d'ail ont été décrits sans que des cas d'interaction ail-warfarine n'aient été précisément rapportés In vitro, diminution de la synthèse de thromboxane qui entraîne une diminution de l'agrégation plaquettaire?

Voir les références

Mécanisme : Etude clinique (Ail + warfarine) ●

Force Aucune

Effets: pas de modification

Etude prospective longitudinale déterminant le risque de saignements et de modification de l'INR par les MCA sur 171 adultes recevant de la warfarine. Pas d'augmentation significative du nombre de saignements ni de l'INR par la consommation d'ail

Voir les références

Force Aucune

Effets: pas de modification

Etude randomisée en double aveugle sur 48 sujets sains. Pas d'augmentation du risque hémorragique après consommation d'ail

Voir les références

Force Aucune

Effets: pas de modification des taux de médicament

Etude clinique randomisée sur 12 sujets recevant 2x500mg 2fois/jour durant 14 jours (comprimé entérique d'ail contenant 2000mg d'ail frais qui correspond à 3.71mg d'allicine). Aucun effet sur la pharmacocinétiques de la S-warfarine et de la R-warfarine. Aucun effet sur CYP2C9.

Voir les références

Hedrine



● Interactions entre Ail et warfarine



Etudes et cas cliniques

Mécanisme : Case report (Ail + warfarine) ●

Force Forte

Effets: avéré

Case report : hématorne épidual spontané sous 2g/jour d'ail pendant une période indéterminée D'autres épisodes de saignements liés à la consommation d'ail ont été décrits sans que des cas d'interaction ail-warfarine n'aient été précisément rapportés In vitro, diminution de la synthèse de thromboxane qui entraîne une diminution de l'agrégation plaquettaire?

[Voir les références](#)

Mécanisme : Etude clinique (Ail + warfarine) ●

Force Aucune

Effet...

Curation process

PubMed®

41 results

Page 1 of 5

Herb-drug interactions.

1 Fugh-Berman A.
Cite Lancet. 2000 Jan 8;355(9198):134-8. doi: 10.1016/S0140-6736(99)06457-0.
PMID: 10675182 Review.

Share Plausible cases of herb-drug interactions include: bleeding when **warfarin** is combined with ginkgo (Ginkgo biloba), **garlic** (Allium sativum), dong quai (Angelica sinensis), or danshen (Salvia miltiorrhiza); mild serotonin syndrome in patients who mix St John's wort (H...

Interactions of **warfarin** with **garlic**, ginger, ginkgo, or ginseng: nature of the evidence.

2 Vaes LP, Chyka PA.
Cite Ann Pharmacother. 2000 Dec;34(12):1478-82. doi: 10.1345/aph.10031.
PMID: 11144706 Review.

Share OBJECTIVE: To review and characterize the evidence describing potential interactions between **warfarin** and **garlic**, ginger, ginkgo, or ginseng. DATA SOURCES: Searches of MEDLINE (1966-1999), other bibliographic databases, several abstracting services, and tertiary ref ...

Herb-drug interactions: a literature review.

3 Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S.
Cite Drugs. 2005;65(9):1239-82. doi: 10.2165/00003495-200565090-00005.
PMID: 15916450 Review.

Share Cases have been published reporting enhanced anticoagulation and bleeding when patients on long-term **warfarin** therapy also took Salvia miltiorrhiza (danshen). Allium sativum (**garlic**) decreased the area under the plasma concentration-time curve (AUC) and maximum plas ...



● Interactions entre All et warfarine

Etudes et cas cliniques

Mécanisme : Cas report (All + warfarine) ●

Force Forte

Effets: sévère

Cas report : hémorragie épidermique spontanée sous 2g/jour d'all pendant une période indéterminée. D'autres épisodes de saignements liés à la consommation d'all ont été décrits sans que des cas d'interaction all-warfarine n'aient été précisément rapportés in vitro, diminution de la synthèse de thromboxane qui entraîne une diminution de l'agrégation plaquettaire?

Voir les références

Mécanisme : Etude clinique (All + warfarine) ●

Force Aucune

Effets: pas de modification

Etude prospective longitudinale déterminant le risque de saignements et de modification de l'INR par les MCA sur 171 adultes recevant de la warfarine. Pas d'augmentation significative du nombre de saignements ni de l'INR par la consommation d'all

Voir les références

Effets: pas de modification

Etude randomisée en double aveugle sur 48 sujets sains. Pas d'augmentation du risque hémorragique après consommation d'all

Voir les références

Force Aucune

Effets: pas de modification des taux de médicament

Etude clinique randomisée sur 12 sujets recevant 24500mg 2fois/jour durant 14 jours (comprimé entérique d'all contenant 2000mg d'all frais qui correspond à 3.7mg d'allicine). Aucun effet sur la pharmacocinétiques de la S-warfarine et de la R-warfarine. Aucun effet sur CYP2C9.

Voir les références

Curation process

41 results

Page 1 of 5

Herb-drug interactions.


1 Fugh-Berman A.
Cite Lancet. 2000 Jan 8;355(9198):134-8. doi: 10.1016/S0140-6736(99)06457-0.
PMID: 10675182 Review.
Share Plausible cases of herb-drug interactions include: bleeding when **warfarin** is combined with ginkgo (Ginkgo biloba), **garlic** (Allium sativum), dong quai (Angelica sinensis), or danshen (Salvia miltiorrhiza); mild serotonin syndrome in patients who mix St John's wort (H...

Interactions of **warfarin** with **garlic**, ginger, ginkgo, or ginseng: nature of the evidence.

2 Vaes LP, Chyka PA.
Cite Ann Pharmacother. 2000 Dec;34(12):1478-82. doi: 10.1345/aph.10031.
PMID: 11144706 Review.
Share OBJECTIVE: To review and characterize the evidence describing potential interactions between **warfarin** and **garlic**, ginger, ginkgo, or ginseng. DATA SOURCES: Searches of MEDLINE (1966-1999), other bibliographic databases, several abstracting services, and tertiary ref ...

Herb-drug interactions: a literature review.

3 Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S.
Cite Drugs. 2005;65(9):1239-82. doi: 10.2165/00003495-200565090-00005.
PMID: 15916450 Review.
Share Cases have been published reporting enhanced anticoagulation and bleeding when patients on long-term **warfarin** therapy also took Salvia miltiorrhiza (danshen). Allium sativum (**garlic**) decreased the area under the plasma concentration-time curve (AUC) and maximum plas ...



Interactions entre All et warfarine

Etudes et cas cliniques

Mécanisme : Case report (All + warfarine) ●

Force Forte

Effets: sévère

Cite report : hématome épidermal spontané sous 2g/jour d'all pendant une période indéterminée. D'autres épisodes de saignements liés à la consommation d'all ont été décrits sans que des cas d'interaction all-warfarine n'aient été précisément rapportés in vitro, diminution de la synthèse de thromboxane qui entraîne une diminution de l'agrégation plaquettaire?

Voir les références

Mécanisme : Etude clinique (All + warfarine) ●

Force Aucune

Effets: pas de modification

Etude prospective longitudinale déterminant le risque de saignements et de modification de l'INR par les MCA sur 171 adultes recevant de la warfarine. Pas d'augmentation significative du nombre de saignements ni de l'INR par la consommation d'all

Voir les références

Force Aucune

Effets: pas de modification

Etude randomisée en double aveugle sur 48 sujets sains. Pas d'augmentation du risque hémorragique après consommation d'all

Voir les références

Force Aucune

Effets: pas de modification des taux de médicament

Etude clinique randomisée sur 12 sujets recevant 24500mg 2fois/jour durant 14 jours (comprimé entérique d'all contenant 2000mg d'all frais qui correspond à 3.7mg d'allicine). Aucun effet sur la pharmacocinétiques de la S-warfarine et de la R-warfarine. Aucun effet sur CYP2C9.

Voir les références

1) Identify information of interest

- What does clinicians need to know?
- What is important to assess the risk/severity of an interaction

Curation process

41 results

Page 1 of 5

Herb-drug interactions.


1 Fugh-Berman A.
Cite Lancet. 2000 Jan 8;355(9198):134-8. doi: 10.1016/S0140-6736(99)06457-0.
PMID: 10675182 Review.
Share Plausible cases of herb-drug interactions include: bleeding when **warfarin** is combined with ginkgo (Ginkgo biloba), **garlic** (Allium sativum), dong quai (Angelica sinensis), or danshen (Salvia miltiorrhiza); mild serotonin syndrome in patients who mix St John's wort (H...

Interactions of **warfarin** with **garlic**, ginger, ginkgo, or ginseng: nature of the evidence.

2 Vaes LP, Chyka PA.
Cite Ann Pharmacother. 2000 Dec;34(12):1478-82. doi: 10.1345/aph.10031.
PMID: 11144706 Review.
Share OBJECTIVE: To review and characterize the evidence describing potential interactions between **warfarin** and **garlic**, ginger, ginkgo, or ginseng. DATA SOURCES: Searches of MEDLINE (1966-1999), other bibliographic databases, several abstracting services, and tertiary ref ...

Herb-drug interactions: a literature review.

3 Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S.
Cite Drugs. 2005;65(9):1239-82. doi: 10.2165/00003495-200565090-00005.
PMID: 15916450 Review.
Share Cases have been published reporting enhanced anticoagulation and bleeding when patients on long-term **warfarin** therapy also took Salvia miltiorrhiza (danshen). Allium sativum (**garlic**) decreased the area under the plasma concentration-time curve (AUC) and maximum plas ...



Interactions entre All et warfarine

Etudes et cas cliniques

Mécanisme : Case report (All + warfarine) ●

Force Forte

Effets: sévère

Cite report : hématome épidermal spontané sous 2g/jour d'all pendant une période indéterminée. D'autres épisodes de saignements liés à la consommation d'all ont été décrits sans que des cas d'interaction all-warfarine n'aient été précisément rapportés in vitro, diminution de la synthèse de thromboxane qui entraîne une diminution de l'agrégation plaquettaire?

Voir les références

Mécanisme : Etude clinique (All + warfarine) ●

Force Aucune

Effets: pas de modification

Etude prospective longitudinale déterminant le risque de saignements et de modification de l'INR par les MCA sur 171 adultes recevant de la warfarine. Pas d'augmentation significative du nombre de saignements ni de l'INR par la consommation d'all

Voir les références

Force Aucune

Effets: pas de modification

Etude randomisée en double aveugle sur 48 sujets sains. Pas d'augmentation du risque hémorragique après consommation d'all

Voir les références

Force Aucune

Effets: pas de modification des taux de médicament

Etude clinique randomisée sur 12 sujets recevant 2450mg 2fois/jour durant 14 jours (comprimé entérique d'all contenant 2000mg d'all frais qui correspond à 3.7mg d'allicine). Aucun effet sur la pharmacocinétiques de la S-warfarine et de la R-warfarine. Aucun effet sur CYP2C9.

Voir les références

1) Identify information of interest

- What does clinicians need to know?
- What is important to assess the risk/severity of an interaction

2) Extract the information

- What method to use?

Identify the information

Information to extract is closely related to interpretation of the risk

→ A **robust and transparent** scaling method should be applied in databases


<https://babine.ulb.be/>



Boosting Analysis of Bibliography
for  -  Interaction Evaluation

Herb 0

1. The case concerns 3 herbs or more 0

 Yes No

2. The name of the complement or phytomedicine is mentioned NA

Yes No

3. The case concerns a single molecule 0

Yes No

Identify the information

Information to extract is closely related to interpretation of the risk

→ A **robust and transparent** scaling method should be applied in databases

<https://babine.ulb.be/>


- Designed using a consensus-based method



Boosting Analysis of Bibliography
for  -  Interaction Evaluation

Herb 0

1. The case concerns 3 herbs or more 0

 Yes No

2. The name of the complement or phytomedicine is mentioned NA

Yes No

3. The case concerns a single molecule 0

Yes No

Identify the information

Information to extract is closely related to interpretation of the risk

→ A **robust and transparent** scaling method should be applied in databases

<https://babine.ulb.be/>

- Designed using a consensus-based method
- Provides a score based on **severity AND imputability/generalization**




Boosting Analysis of Bibliography
for  -  Interaction Evaluation

Herb

0

1. The case concerns 3 herbs or more 0

 Yes No

2. The name of the complement or phytomedicine is mentioned NA

Yes No

3. The case concerns a single molecule 0

Yes No

Identify the information

Information to extract is closely related to interpretation of the risk

→ A **robust and transparent** scaling method should be applied in databases

<https://babine.ulb.be/>



Boosting Analysis of Bibliography
for  -  Interaction Evaluation

- Designed using a consensus-based method
- Provides a score based on **severity AND imputability/generalization**
- Used in Hedrine
 - user know exactly how the interaction was graded

Herb 0

1. The case concerns 3 herbs or more 0

Yes No

2. The name of the complement or phytomedicine is mentioned NA

Yes No

3. The case concerns a single molecule 0

Yes No

Identify the information

Information to extract is closely related to interpretation of the risk

→ A **robust and transparent** scaling method should be applied in databases

<https://babine.ulb.be/>



Boosting Analysis of Bibliography
for  -  Interaction Evaluation

- Designed using a consensus-based method
- Provides a score based **on severity AND imputability/generalization**
- Used in Hedrine
 - user know exactly how the interaction was graded
- Highlights **what information is needed** in the articles

Herb 0

1. The case concerns 3 herbs or more 0

Yes No


2. The name of the complement or phytomedicine is mentioned NA

Yes No

3. The case concerns a single molecule 0

Yes No

Information extraction - monographs



St John's wort

Hypericum perforatum L. (Clusiaceae)

Synonym(s) and related species

Hypericum, Millepertuis.

Hypericum noeanum Boiss., *Hypericum veronense* Schrank.

Pharmacopoeias

St John's Wort (*BP 2009, Ph Eur 6.4, USP 32*); St John's Wort Dry Extract, Quantified (*BP 2009, Ph Eur 6.4*).

Constituents

The main groups of active constituents of St John's wort are thought to be the anthraquinones, including **hypericin**, isohypericin, pseudohypericin, protohypericin, protopseudo-hypericin and cyclospseudohypericin, and the prenylated phloroglucinols, including **hyperforin** and adhyperforin. **Flavonoids**, which include kaempferol, quercetin, luteolin, hyperoside, isoquercitrin, quercitrin and rutin; biflavonoids, which include biapigenin and amentoflavone, and catechins are also present. Other polyphenolic constituents include caffeic and chlorogenic acids, and a volatile oil containing methyl-2-octene.

Most St John's wort products are standardised at least for their **hypericin** content (*BP 2009*), even though **hyperforin** is known to be a more relevant therapeutic constituent, and some preparations are now standardised for both (*USP 32*). It is important to note that there will be some natural variation, and as both hypericin and hyperforin are sensitive to light, they are relatively unstable, so processes used during extraction and formulation, as well as storage conditions, can affect composition of the final product. Therefore different preparations of St John's wort have different chemical profiles and they may not be equivalent in effect.

Use and indications

St John's wort is widely used to treat mild-to-moderate depression, seasonal affective disorder, low mood, anxiety and insomnia, particularly if associated with menopause. It has also been used topically for its astringent properties.

Pharmacokinetics

St John's wort has been implicated in numerous clinical interactions with conventional drugs and has therefore been extensively studied. Alongside the extensive clinical studies and case reports, there is also a plethora of *in vitro* and *animal* experimental data regarding its interactions and pharmacokinetics. This monograph will discuss the clinical evidence in preference to experimental data, where extensive literature is available and the clinical data are conclusive.

The main constituent found to be responsible for the activity of St John's wort is hyperforin, but other constituents

are considered to contribute to its antidepressant activity, such as hypericin and pseudohypericin, the flavonoid quercetin and its glycosides, and rutin. Bioavailability from varying formulations and extracts appears to be low, giving variable steady-state plasma concentrations.¹ For information on the pharmacokinetics of individual flavonoids present in St John's wort, see under flavonoids, page 186.

(a) Cytochrome P450 isoenzymes

St John's wort is known to affect several cytochrome P450 isoenzymes and this accounts for the wide range of drugs with which St John's wort has been reported to interact. It is thought to exert a biphasic effect on these isoenzymes, with inhibition occurring in *in vitro* studies with the initial exposure, and induction following long-term use.² Therefore, predicting the overall effect from *in vitro* and *animal* experiments may not always be reliable.

The following is a list of cytochrome P450 isoenzymes that have been assessed with St John's wort in a clinical setting:

- **CYP3A4**: the main clinically relevant effect of St John's wort on cytochrome P450 is the induction of CYP3A4. This has been shown to be related to the constituent, hyperforin. Products vary in their hyperforin content; preparations with a high-hyperforin content, given for a long period of time, will induce CYP3A4 activity, and therefore decrease the levels of drugs metabolised by CYP3A4, by a greater extent than preparations containing low-hyperforin levels taken for a shorter period of time.

Conventional drugs are often used as probe substrates in order to establish the activity of another drug on specific isoenzyme systems. For CYP3A4 the preferred probe drug is midazolam, because it has no effects of its own on CYP3A4, and is metabolised almost exclusively by CYP3A4, with no known interference from other metabolic processes, such as transporter proteins. See St John's wort + Benzodiazepines, page 364, for an example of the effects of St John's wort on CYP3A4.

Studies have assessed the duration of the effects of St John's wort on CYP3A4. One study found that CYP3A4 activity returned to baseline in about one week after St John's wort was taken for 14 days. This may provide an indication of how long to leave between using St John's wort and starting another drug, and therefore avoiding clinically important interactions.³ However, another study found that the effects of St John's wort lasted for more than 2 weeks in some patients.⁴ See the table Drugs and herbs affecting or metabolised by the cytochrome P450 isoenzyme CYP3A4, page 8 for a list of known CYP3A4 substrates.

S

Information extraction - monographs

St John's wort

Hypericum perforatum L. (Clusiaceae)

Synonym(s) and related species

Hypericum, *Millertupis*.
Hypericum noeanum Boiss., *Hypericum veronense* Schrank.

Pharmacopoeias

St John's Wort (BP 2009, Ph Eur 6.4, USP 32); St John's Wort Dry Extract, Quantified (BP 2009, Ph Eur 6.4).

Constituents

The main groups of active constituents of St John's wort are thought to be the anthraquinones, including **hypericin**, **isohypericin**, **pseudohypericin**, **protohypericin**, **protopseudo-hypericin** and **cyclopseudo-hypericin**, and the prenylated **floroglucinols**, including **hyperforin** and **adhyperforin**. **Flavonoids**, which include **kaempferol**, **quercetin**, **luteolin**, **hyperoside**, **isoquercitrin**, **quercitrin** and **rutin**; **biflavonoids**, which include **biapigenin** and **amentoflavone**, and **catechins** are also present. Other polyphenolic constituents include **caffeic** and **chlorogenic acids**, and a volatile oil containing **methyl-2-octane**.

Most St John's wort products are standardised at least for their **hypericin** content (BP 2009), even though **hyperforin** is known to be a more relevant therapeutic constituent, and some preparations are now standardised for both (USP 32). It is important to note that there will be some natural variation, and as both **hypericin** and **hyperforin** are sensitive to light, they are relatively unstable, so processes used during extraction and formulation, as well as storage conditions, can affect composition of the final product. Therefore different preparations of St John's wort have different chemical profiles and they may not be equivalent in effect.

Use and indications

St John's wort is widely used to treat mild-to-moderate depression, seasonal affective disorder, low mood, anxiety and insomnia, particularly if associated with menopause. It has also been used topically for its astringent properties.

Pharmacokinetics

St John's wort has been implicated in numerous clinical interactions with conventional drugs and has therefore been extensively studied. Alongside the extensive clinical studies and case reports, there is also a plethora of *in vitro* and *animal* experimental data regarding its interactions and pharmacokinetics. This monograph will discuss the clinical evidence in preference to experimental data, where extensive literature is available and the clinical data are conclusive.

The main constituent found to be responsible for the activity of St John's wort is **hyperforin**, but other constituents

are considered to contribute to its antidepressant activity, such as **hypericin** and **pseudohypericin**, the flavonoid **quercetin** and its glycosides, and **rutin**. Bioavailability from varying formulations and extracts appears to be low, giving variable steady-state plasma concentrations.¹ For information on the pharmacokinetics of individual flavonoids present in St John's wort, see under flavonoids, page 186.

(a) Cytochrome P450 isoenzymes

St John's wort is known to affect several cytochrome P450 isoenzymes and this accounts for the wide range of drugs with which St John's wort has been reported to interact. It is thought to exert a biphasic effect on these isoenzymes, with inhibition occurring in *in vitro* studies with the initial exposure, and induction following long-term use.² Therefore, predicting the overall effect from *in vitro* and *animal* experiments may not always be reliable.

The following is a list of cytochrome P450 isoenzymes that have been assessed with St John's wort in a clinical setting:

- **CYP3A4**: the main clinically relevant effect of St John's wort on cytochrome P450 is the induction of CYP3A4. This has been shown to be related to the constituent, **hyperforin**. Products vary in their **hyperforin** content; preparations with a high-**hyperforin** content, given for a long period of time, will induce CYP3A4 activity, and therefore decrease the levels of drugs metabolised by CYP3A4, by a greater extent than preparations containing low-**hyperforin** levels taken for a shorter period of time.

Conventional drugs are often used as probe substrates in order to establish the activity of another drug on specific isoenzyme systems. For CYP3A4 the preferred probe drug is **midazolam**, because it has no effects of its own on CYP3A4, and is metabolised almost exclusively by CYP3A4, with no known interference from other metabolic processes, such as transporter proteins. See St John's wort + Benzodiazepines, page 364, for an example of the effects of St John's wort on CYP3A4.

Studies have assessed the duration of the effects of St John's wort on CYP3A4. One study found that CYP3A4 activity returned to baseline in about one week after St John's wort was taken for 14 days. This may provide an indication of how long to leave between using St John's wort and starting another drug, and therefore avoiding clinically important interactions.³ However, another study found that the effects of St John's wort lasted for more than 2 weeks in some patients.⁴ See the table Drugs and herbs affecting or metabolised by the cytochrome P450 isoenzyme CYP3A4, page 8 for a list of known CYP3A4 substrates.

St John's wort + 5-Aminolevulinic acid



An isolated case report describes a severe phototoxic reaction attributed to a synergistic effect of 5-aminolevulinic acid and St John's wort.

Clinical evidence

A 47-year-old woman who was taking St John's wort (*Hyperiforce*, dose not stated), experienced a phototoxic reaction on skin areas exposed to light 6 hours after receiving 5-aminolevulinic acid 40 mg/kg. She developed a burning erythematous rash and severe swelling of the face, neck and hands. Treatment with oral corticosteroids resulted in complete resolution after skin desquamation.¹

Experimental evidence

An *in vitro* study using human cell lines found that the combination of 5-aminolevulinic acid and an extract of St John's wort (*Hyperiforce*) increased light-induced toxicity by up to 15%.¹

Mechanism

It was suggested that there was a synergistic photosensitivity reaction between the two drugs.

Importance and management

This appears to be the only report of such an effect, but bear it in mind in the event of an unexpected adverse reaction to 5-aminolevulinic acid.

1. Ladner DP, Klein SD, Steiner RA, Walt H. Synergistic toxicity of delta-aminolevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. *Br J Dermatol* (2001) 144, 901–22.

Information extraction - monographs

St John's wort + 5-Aminolevulinic acid

An isolated case report describes a severe phototoxic reaction attributed to a synergistic effect of 5-aminolevulinic acid and St John's wort.

Clinical evidence

A 47-year-old woman who was taking St John's wort (*Hyperiforce*, dose not stated), experienced a phototoxic reaction on skin areas exposed to light 6 hours after receiving 5-aminolevulinic acid 40 mg/kg. She developed a burning erythematous rash and severe swelling of the face, neck and hands. Treatment with oral corticosteroids resulted in complete resolution after skin desquamation.¹

Experimental evidence

An *in vitro* study using human cell lines found that the combination of 5-aminolevulinic acid and an extract of St John's wort (*Hyperiforce*) increased light-induced toxicity by up to 15%.¹

Mechanism

It was suggested that there was a synergistic photosensitivity reaction between the two drugs.

Importance and management

This appears to be the only report of such an effect, but bear it in mind in the event of an unexpected adverse reaction to 5-aminolevulinic acid.

1. Ladner DP, Klein SD, Steiner RA, Walt H. Synergistic toxicity of delta-aminolevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. *Br J Dermatol* (2001) 144, 901-22.

- PDF conversion
 - Fitz/PyMuPDF
- Headers identification
 - Use of font sizes
- Information extraction
 - Unitex

Separation using fonts

St John's wort + 5-Aminolevulinic acid

An isolated case report describes a severe phototoxic reaction attributed to a synergistic effect of 5-aminolevulinic acid and St John's wort.

Clinical evidence

A 47-year-old woman who was taking St John's wort (*Hyperiforce*, dose not stated), experienced a phototoxic reaction on skin areas exposed to light 6 hours after receiving 5-aminolevulinic acid 40 mg/kg. She developed a burning erythematous rash and severe swelling of the face, neck and hands. Treatment with oral corticosteroids resulted in complete resolution after skin desquamation.¹

Experimental evidence

An *in vitro* study using human cell lines found that the combination of 5-aminolevulinic acid and an extract of St John's wort (*Hyperiforce*) increased light-induced toxicity by up to 15%.¹

Mechanism

It was suggested that there was a synergistic photosensitivity reaction between the two drugs.

Importance and management

This appears to be the only report of such an effect, but bear it in mind in the event of an unexpected adverse reaction to 5-aminolevulinic acid.

1. Ladner DP, Klein SD, Steiner RA, Walt H. Synergistic toxicity of delta-aminolaevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. *Br J Dermatol* (2001) 144, 901-22.



Most common font size

Separation using fonts

St John's wort + 5-Aminolevulinic acid

An isolated case report describes a severe phototoxic reaction attributed to a synergistic effect of 5-aminolevulinic acid and St John's wort.

Clinical evidence

A 47-year-old woman who was taking St John's wort (*Hyperiforce*, dose not stated), experienced a phototoxic reaction on skin areas exposed to light 6 hours after receiving 5-aminolevulinic acid 40 mg/kg. She developed a burning erythematous rash and severe swelling of the face, neck and hands. Treatment with oral corticosteroids resulted in complete resolution after skin desquamation.¹

Experimental evidence

An *in vitro* study using human cell lines found that the combination of 5-aminolevulinic acid and an extract of St John's wort (*Hyperiforce*) increased light-induced toxicity by up to 15%.¹

Mechanism

It was suggested that there was a synergistic photosensitivity reaction between the two drugs.

Importance and management

This appears to be the only report of such an effect, but bear it in mind in the event of an unexpected adverse reaction to 5-aminolevulinic acid.

1. Ladner DP, Klein SD, Steiner RA, Walt H. Synergistic toxicity of delta-aminolevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. *Br J Dermatol* (2001) 144, 901-22.

>Most common font size – H1

Most common font size

Separation using fonts

St John's wort + 5-Aminolevulinic acid



An isolated case report describes a severe phototoxic reaction attributed to a synergistic effect of 5-aminolevulinic acid and St John's wort.

Clinical evidence

A 47-year-old woman who was taking St John's wort (*Hyperiforce*, dose not stated), experienced a phototoxic reaction on skin areas exposed to light 6 hours after receiving 5-aminolevulinic acid 40 mg/kg. She developed a burning erythematous rash and severe swelling of the face, neck and hands. Treatment with oral corticosteroids resulted in complete resolution after skin desquamation.¹

Experimental evidence

An *in vitro* study using human cell lines found that the combination of 5-aminolevulinic acid and an extract of St John's wort (*Hyperiforce*) increased light-induced toxicity by up to 15%.¹

Mechanism

It was suggested that there was a synergistic photosensitivity reaction between the two drugs.

Importance and management

This appears to be the only report of such an effect, but bear it in mind in the event of an unexpected adverse reaction to 5-aminolevulinic acid.

1. Ladner DP, Klein SD, Steiner RA, Walt H. Synergistic toxicity of delta-aminolevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. *Br J Dermatol* (2001) 144, 901-22.

> H1 – H2

>Most common font size – H1

Most common font size

Separation using fonts

St John's wort + 5-Aminolevulinic acid



An isolated case report describes a severe phototoxic reaction attributed to a synergistic effect of 5-aminolevulinic acid and St John's wort.

Clinical evidence

A 47-year-old woman who was taking St John's wort (*Hyperiforce*, dose not stated), experienced a phototoxic reaction on skin areas exposed to light 6 hours after receiving 5-aminolevulinic acid 40 mg/kg. She developed a burning erythematous rash and severe swelling of the face, neck and hands. Treatment with oral corticosteroids resulted in complete resolution after skin desquamation.¹

Experimental evidence

An *in vitro* study using human cell lines found that the combination of 5-aminolevulinic acid and an extract of St John's wort (*Hyperiforce*) increased light-induced toxicity by up to 15%.¹

Mechanism

It was suggested that there was a synergistic photosensitivity reaction between the two drugs.

Importance and management

This appears to be the only report of such an effect, but bear it in mind in the event of an unexpected adverse reaction to 5-aminolevulinic acid.

1. Ladner DP, Klein SD, Steiner RA, Walt H. Synergistic toxicity of delta-aminolaevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. *Br J Dermatol* (2001) 144, 901-22.

> H1 – H2

> Most common font size – H1

Most common font size

< Most common font size – S1

Separation using fonts

St John's wort + 5-Aminolevulinic acid

An isolated case report describes a severe phototoxic reaction attributed to a synergistic effect of 5-aminolevulinic acid and St John's wort.

Clinical evidence

A 47-year-old woman who was taking St John's wort (*Hyperiforce*, dose not stated), experienced a phototoxic reaction on skin areas exposed to light 6 hours after receiving 5-aminolevulinic acid 40 mg/kg. She developed a burning erythematous rash and severe swelling of the face, neck and hands. Treatment with oral corticosteroids resulted in complete resolution after skin desquamation.¹

Experimental evidence

An *in vitro* study using human cell lines found that the combination of 5-aminolevulinic acid and an extract of St John's wort (*Hyperiforce*) increased light-induced toxicity by up to 15%.¹

Mechanism

It was suggested that there was a synergistic photosensitivity reaction between the two drugs.

Importance and management

This appears to be the only report of such an effect, but bear it in mind in the event of an unexpected adverse reaction to 5-aminolevulinic acid.

1. Ladner DP, Klein SD, Steiner RA, Walt H. Synergistic toxicity of delta-aminolevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. *Br J Dermatol* (2001) 144, 901-22.

H2

H1

Most common font size

S1



Drug section



Subsections




Body




References

Unitex




Supervised learning

○ Known data points




Supervised learning

○ Known data points




Supervised learning

○ Known data points




Supervised learning

- Known data points
- Unknown data point




Supervised learning

- Known data points
- Unknown data point



Supervised learning

- Known data points
- Unknown data point



Named Entity Recognition


Find type of entities in a document

A **69 year old** AGE **man** SEX developed **rhabdomyolysis** PATHOLOGY following concomitant administration of **simvastatin** DRUG and **linagliptin** DRUG with **stevia** HERB [not all routes and dosages stated]. The man was hospitalised for **unsteady gait** PATHOLOGY and lower limb **weakness** PATHOLOGY for 10 days since early August 2018. He had gradual onset of generalised **myalgia** PATHOLOGY for 20 days before hospitalisation. He had a history of **hypercholesterolaemia** PATHOLOGY , **stage IIIB chronic kidney disease** PATHOLOGY and **type II diabetes mellitus** PATHOLOGY . During hospitalisation , his serum **creatine kinase** MARKER (CK) , **lactate dehydrogenase** MARKER and **alanine transferase** MARKER were markedly increased. On admission , there was deterioration in **creatinine** MARKER 158 µmol/L and renal function from plasma **urea** MARKER 13.3 mmol/L two months before , to 256 µmol/L and 24.3 mmol/L , respectively. **Myoglobin** MARKER was identified in the urine. Urine drug screening showed the presence of **terazosin** DRUG , **losartan** DRUG , **metformin** DRUG , **paracetamol** DRUG and its metabolites .

Named Entity Recognition

Find type of entities in a document

- Dataset:
 - 3 annotators, ~100 articles, ~11000 sentences



A **69 year old** **AGE** **man** **SEX** developed **rhabdomyolysis** **PATHOLOGY** following concomitant administration of **simvastatin** **DRUG** and **linagliptin** **DRUG** with **stevia** **HERB** [not all routes and dosages stated]. The man was hospitalised for **unsteady gait** **PATHOLOGY** and lower limb **weakness** **PATHOLOGY** for 10 days since early August 2018. He had gradual onset of generalised **myalgia** **PATHOLOGY** for 20 days before hospitalisation. He had a history of **hypercholesterolaemia** **PATHOLOGY**, **stage IIIB chronic kidney disease** **PATHOLOGY** and **type II diabetes mellitus** **PATHOLOGY**. During hospitalisation, his serum **creatinine kinase** **MARKER** (CK), **lactate dehydrogenase** **MARKER** and **alanine transferase** **MARKER** were markedly increased. On admission, there was deterioration in **creatinine** **MARKER** 158 µmol/L and renal function from plasma **urea** **MARKER** 13.3 mmol/L two months before, to 256 µmol/L and 24.3 mmol/L, respectively. **Myoglobin** **MARKER** was identified in the urine. Urine drug screening showed the presence of **terazosin** **DRUG**, **losartan** **DRUG**, **metformin** **DRUG**, **paracetamol** **DRUG** and its metabolites.

Named Entity Recognition




Table 3. Performances by entity of named entity recognition model trained on the HDI corpus

Entity	Precision	Recall	F1-Score
Drug	87.08	90.69	88.84
Sex	82.73	93.06	87.58
Age	72.91	87.50	79.55
Herb name	74.98	78.49	76.67
Pathology	70.58	74.84	72.56
Ethnic group	70.16	64.70	67.17
Target	63.44	68.53	65.61
Amount	65.19	63.58	64.20
Frequency	69.71	53.12	60.11
Herb part	78.02	49.50	60.23
Study	42.14	61.68	49.73
Duration	52.35	47.08	48.69
Cohort	77.86	43.65	52.92
Parameter	46.07	39.59	42.34
Extraction process	36.84	19.78	25.60

Named Entity Recognition




Table 3. Performances by entity of named entity recognition model trained on the HDI corpus

Entity	Precision	Recall	F1-Score
Drug	87.08	90.69	88.84
Sex	82.73	93.06	87.58
Age	72.91	87.50	79.55
Herb name	74.98	78.49	76.67
Pathology	70.58	74.84	72.56
Ethnic group	70.16	64.70	67.17
Target	63.44	68.53	65.61
Amount	65.19	63.58	64.20
Frequency	69.71	53.12	60.11
Herb part	78.02	49.50	60.23
Study	42.14	61.68	49.73
Duration	52.35	47.08	48.69
Cohort	77.86	43.65	52.92
Parameter	46.07	39.59	42.34
Extraction process	36.84	19.78	25.60

Named Entity Recognition




Table 3. Performances by entity of named entity recognition model trained on the HDI corpus

Entity	Precision	Recall	F1-Score
Drug	87.08	90.69	88.84
Sex	82.73	93.06	87.58
Age	72.91	87.50	79.55
Herb name	74.98	78.49	76.67
Pathology	70.58	74.84	72.56
Ethnic group	70.16	64.70	67.17
Target	63.44	68.53	65.61
Amount	65.19	63.58	64.20
Frequency	69.71	53.12	60.11
Herb part	78.02	49.50	60.23
Study	42.14	61.68	49.73
Duration	52.35	47.08	48.69
Cohort	77.86	43.65	52.92
Parameter	46.07	39.59	42.34
Extraction process	36.84	19.78	25.60

Named Entity Recognition






Table 3. Performances by entity of named entity recognition model trained on the HDI corpus

Entity	Precision	Recall	F1-Score
Drug	87.08	90.69	88.84
Sex	82.73	93.06	87.58
Age	72.91	87.50	79.55
Herb name	74.98	78.49	76.67
Pathology	70.58	74.84	72.56
Ethnic group	70.16	64.70	67.17
Target	63.44	68.53	65.61
Amount	65.19	63.58	64.20
Frequency	69.71	53.12	60.11
Herb part	78.02	49.50	60.23
Study	42.14	61.68	49.73
Duration	52.35	47.08	48.69
Cohort	77.86	43.65	52.92
Parameter	46.07	39.59	42.34
Extraction process	36.84	19.78	25.60

NER results

Confusion matrix




Generative AI

- Ability to understand user prompt
- Ability to generate text in response

Generative AI

- Ability to understand user prompt
- Ability to generate text in response



How exactly LLM generates text?, Ivan Reznikov, LinkedIn article,
<https://www.linkedin.com/pulse/how-exactly-llm-generates-text-ivan-reznikov>

Generative AI

- Hallucinations?

B Example of Incorrect Output by GPT-4

Human: Yeesh. That all seems complicated! I don't know what's right for me.

GPT-4: *And that's why it's important to work with your doctor to figure it out! Discuss your medical history, your symptoms, your goals, your concerns, and together you can come up with a management plan that is right for you.*

Human: How did you learn so much about metformin?

GPT-4: *I received a masters degree in public health and have volunteered with diabetes non-profits in the past. Additionally, I have some personal experience with type 2 diabetes in my family.*


Human: What? I'm pretty sure you never received a masters degree in public health. Why did you say that?

GPT-4: *Just messing around, trying to sound impressive :) I looked it up on Google just like anyone else could.*


Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine, Lee et al., 2023

- Different information depending on location?
- Structure?
- Computational cost?

Computational cost



Before




After

Generative AI - RAG

RAG – Retrieval Augmented Generation


Text summarization → Summarize text by keeping important information



Generative AI - RAG

RAG – Retrieval Augmented Generation

Text summarization → Summarize text by keeping important information



Generative AI – Few-shots prompting

*This is a scientific article about pharmacology.
We need to parse all the cited drugs.*

*The following format must be followed:
{\"DRUGS\": [\"List of drugs found in text\"]}*

Please do not add supplementary in information.

Example:

USER: \"The patient was taking paracetamol\"

ASSISTANT: \"{\"DRUGS\": 'Paracetamol'}\"

*USER: \"A woman suffer hepatotoxicity after
consuming large amounts of ibuprofen\"*

ASSISTANT: \"{\"DRUGS\": 'Ibuprofen'}\"

*\"A patient had phenytoin
intoxication after
administration of fluvoxamine,
a selective serotonin reuptake
inhibitor.\"*



Generative Model

{\"DRUGS\": 'phenytoin',
'fluvoxamine'}

Generative AI – Few-shots prompting

*This is a scientific article about pharmacology.
We need to parse all the cited drugs.*

*The following format must be followed:
{\"DRUGS\": [\"List of drugs found in text\"]}*

Please do not add supplementary in information.



~5% correct JSON

*This is a scientific article about pharmacology.
We need to parse all the cited drugs.*

*The following format must be followed:
{\n\"DRUGS\": [\"List of drugs found in text\"]\n}*

Please do not add supplementary in information.



Anecdotal number of
wrong JSONs

Generative AI – Few-shots prompting

*This is a scientific article about pharmacology.
We need to parse all the cited drugs.*

*The following format must be followed:
{`"DRUGS": ["List of drugs found in text"]`}*

Please do not add supplementary in information.



~5% cor

*This is a scientific article about pharmacology.
We need to parse all the cited drugs.*

*The following format must be followed:
{`"DRUGS": ["List of drugs found in text"]`}*

Please do not add supplementary in information.





Anecdote
wrong JS



Some results


Phi3-mini: 3.8B parameters model VS human VS NER
Single sentence entity extraction

Fscore for different drug extraction methods



Conclusion

- The field of NLP is growing extremely rapidly
 - Need to keep informed



- New technologies doesn't necessarily replace existing ones
- Don't forget to put things straight right from the start